This is a discussion on TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed within the Updates from the Technology Assessment Authorities forum, part of the Industry News and Updates category; The summary for the published technology appraisal on Lung cancer (non-small cell, first line treatment) - pemetrexed . It links to ...
|
|||||||
| Register | Help | Members List | Mark Forums Read |
|
|||
|
The summary for the published technology appraisal on Lung cancer (non-small cell, first line treatment) - pemetrexed . It links to the published guidance and key documents.
More... Last edited by chantell.reagan : 09-24-2009 at 01:41 PM. |
![]() |
| Thread Tools | |
| Display Modes | |
|
|
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| TA169: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma | industry_news | Updates from the Technology Assessment Authorities | 0 | 03-24-2009 09:20 PM |
| TA162: Lung cancer (non-small-cell) - erlotinib | industry_news | Updates from the Technology Assessment Authorities | 0 | 11-26-2008 12:03 AM |
| Gefitinib as Effective as Docetaxel in Non-Small-Cell Lung Cancer | industry_news | Other Clinical Pharmacy News | 0 | 11-25-2008 06:13 PM |
| First-Line Chemo for Small-Cell Lung Cancer is Not Superior to Second-Line | industry_news | Other Clinical Pharmacy News | 0 | 10-08-2008 09:21 AM |
| Gefitinib for First-Line Therapy in Certain Asian Lung Cancer Patients | industry_news | Other Clinical Pharmacy News | 0 | 09-15-2008 06:19 PM |